Even as COVID-19 continues to spread around the world, researchers are focusing on vaccine and antiviral development. The target of much of this study is the spike (S) protein of severe acute ...
Neutralizing antibodies that merely block receptor binding are losing ground against heavily mutated SARS-CoV-2 Omicron sub-variants. A new approach now exploits a llama-derived nanobody—VHH21—that ...
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results